OBSOLETE: Anthracycline extravasation

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

1 event
Sep 2007

Totect(r): FDA approved

Treatment of extravasation resulting from IV anthracycline chemotherapy

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for OBSOLETE: Anthracycline extravasation.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Totect

(dexrazoxane)Orphan drug

Clinigen, Inc.

12.1 Mechanism of Action The mechanism by which dexrazoxane for injection exerts its cytoprotective activity is not fully understood. Dexrazoxane is a...

Approved Sep 2007FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for OBSOLETE: Anthracycline extravasation.
Search all trials →
Search clinical trials for OBSOLETE: Anthracycline extravasation

Recent News & Research

No recent news articles indexed yet for OBSOLETE: Anthracycline extravasation.
Search PubMed for OBSOLETE: Anthracycline extravasation

Browse all OBSOLETE: Anthracycline extravasation news →

Specialist Network

No specialists currently listed for OBSOLETE: Anthracycline extravasation.

View all OBSOLETE: Anthracycline extravasation specialists →

Quick Actions